CAGW has long been concerned with the misuse of the 340B Program.
New Study Exposes More Exploitation and Waste in the 340B Drug Discount Program
A new study, “The 340B Drug Discount Program Exceeds $100B in 2022,” shows the program is misused.
New Study Confirms 340B Program is Exploited
A new study, “340B and Health Equity: A Missed Opportunity in Medically Underserved Areas,” shows the program is misused.
No Government Price Controls to Pay for Biden’s Gargantuan Spending Bill
Sen. Ron Wyden (D-Ore.) wants to use price controls in Medicare Part D to pay for President Biden’s extravagant spending.
Biden Budget Offers Potential Oversight Tool on 340B Program
The Biden administration’s budget includes new enforcement tools for oversight of the 340B program but the details will matter.
Problems Continue with 340B Program
Berkeley Research Group report shows once again how 340B has been corrupted and is being abused.
Most Favored Nation Policy: Unfavorable to U.S. Pharmaceutical Research
President Trump signs controversial Executive Order (EO) implementing “most favored nation” policy to lower drug costs.
Wasteful Spending on 340B Keeps Growing and Growing
Amid the COVID-19 pandemic response, the 340B drug safety-net program problems seem to have gotten lost.
Hospitals Serving Vulnerable Communities Chase Profits at the Expense of Patients
Patients receiving hospital care don’t know if they will get stuck with enormous and unexpected bills when they are released.
Another Trump Administration Proposed Regulation to Lower Drug Costs for Seniors
Centers for Medicare and Medicaid seeks to revise how Medicare will pay for outpatient drugs under the 340B drug discount program.